Our experienced senior management team members have held senior executive roles at multinational pharmaceutical companies and many led the development and regulatory approvals of pharmaceutical products in markets around the globe. Our research and development team members played a key role in the clinical development of numerous significant drugs, including Herceptin, Rituxan, Xeloda, Pegasys, PEG-Intron, Rebetol, IV Temodol, Requip, Suboxone, Subutex and Nothera. The leadership of our commercial team has launched more than 50 drugs and drug products in multiple markets around the world. A number of our executive officers have significant experience in corporate governance matters, public capital markets transactions, licensing and partnerships, and mergers and acquisitions. We believe this unique combination of executive skill sets has the potential to create substantial long term value for investors.
Athenex Global Harmonization meeting held June 8-10, 2018 in Buffalo, NY (USA)